INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
30.01.25
15:29 Uhr
1,640 Euro
+0,050
+3,14 %
+3,14 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Innate Pharma SA: Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors | 188 | Business Wire | IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate"... ► Artikel lesen | |
| 21.01. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.01. | Innate Pharma SA: Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York | 179 | Business Wire | Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate"... ► Artikel lesen | |
| 21.01. | Innate Pharma SA: Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York | 244 | Business Wire | Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate"... ► Artikel lesen | |
| 16.01. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024 | 243 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 10.01. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.01. | Innate Pharma SA: Innate Pharma Announces Transformative Strategy to Accelerate Growth | 267 | Business Wire | Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET NK-cell engager Platform Accelerate... ► Artikel lesen | |
| 20.12.24 | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.12.24 | Innate Pharma SA: Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference | 243 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P.... ► Artikel lesen | |
| 09.12.24 | Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024 | 11 | Seeking Alpha | ||
| 09.12.24 | Innate Pharma SA: Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma | 344 | Business Wire | Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas
Regulatory News:
Innate Pharma SA (Euronext Paris:... ► Artikel lesen | |
| 06.12.24 | Innate Pharma SA: Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma | 385 | Business Wire | Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma... ► Artikel lesen | |
| 03.12.24 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.12.24 | Innate Pharma SA: Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 | 352 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that abstracts related to lacutamab health-related quality of life and translational... ► Artikel lesen | |
| 20.11.24 | Innate Pharma SA: Innate Pharma Releases Its 2025 Financial Calendar | 114 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2025 financial calendar:
March 27, 2025: Publication of 2024 financial... ► Artikel lesen | |
| 19.11.24 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.24 | Innate Pharma SA: Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 | 302 | Business Wire | IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL IPH6501 boosts NK cell proliferation and cytotoxicity, showing... ► Artikel lesen | |
| 13.11.24 | Innate Pharma reports 9M results | 5 | Seeking Alpha | ||
| 13.11.24 | Innate Pharma SA: Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results | 419 | Business Wire | Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related... ► Artikel lesen | |
| 08.11.24 | Innate Pharma SA: Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 | 367 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that new preclinical data supporting the clinical development of its proprietary... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 116,60 | +0,34 % | Nach Gates-Besuch: BioNTech-Aktie legt deutlich zu | Die Aktie von BioNTech hat am Donnerstag einen deutlichen Kurssprung hinlegen können. Unterstützung erhielt das Papier dabei vom Besuch des Microsoft-Gründers Bill Gates in dieser Woche. Zudem hat das... ► Artikel lesen | |
| MEDIGENE | 1,700 | -1,67 % | PTA-Adhoc: Medigene AG: Medigene AG übt erste Tranche des Standby Equity Purchase Agreements aus | DJ PTA-Adhoc: Medigene AG: Medigene AG übt erste Tranche des Standby Equity Purchase Agreements aus
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Planegg/Martinsried (pta/24.01.2025/18:10)... ► Artikel lesen | |
| CUREVAC | 3,704 | +1,04 % | CureVac Aktie testet 200-Tage-Linie: Kommt neuer Kursschub? | Die CureVac Aktie hat sich seit den beiden Baissetiefs aus dem Jahr 2024 bei 2,22/2,37 Dollar zuletzt wieder spürbar erholt. Die jüngste Rallye startete bei 2,37 Dollar und führte den Kurs am 7. Januar... ► Artikel lesen | |
| QIAGEN | 42,390 | 0,00 % | Biotech Report: Evotec fest, Qiagen gehen leichter ins Wochenende | (shareribs.com) Frankfurt / New York 24.01.2025 - Biotech-Aktien tendieren am Freitag uneinheitlich. Für Qiagen geht es abwärts, während Evotec zulegen kann. An der Wall Street kann der Sektor zulegen.... ► Artikel lesen | |
| AMGEN | 271,95 | -0,37 % | Amgen Set to Report Q4 Earnings: Is a Beat in the Cards? | ||
| NOVAVAX | 8,700 | +0,54 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| CRISPR THERAPEUTICS | 40,400 | +1,51 % | Jim Cramer Says "CRISPR (CRSP) Keeps Losing Money Like Moderna" - Here's Why | ||
| REGENERON PHARMACEUTICALS | 658,60 | +0,34 % | Leerink Partnrs Issues Positive Forecast for REGN Earnings | ||
| ORGANOVO | 0,333 | +0,45 % | Organovo, Inc.: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,000 | -0,99 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,155 | -1,89 % | Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts | ||
| INFLARX | 2,204 | -2,39 % | Inflarx-Zulassung: Hoffnung über COVID-19 hinaus | ||
| VIKING THERAPEUTICS | 32,580 | +0,59 % | Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? | ||
| INTELLIA THERAPEUTICS | 10,220 | +1,14 % | How Is The Market Feeling About Intellia Therapeutics? | ||
| BIO-GATE | 0,810 | +2,53 % | Bio-Gate: Prognose reduziert, Potenzial aber weiter hoch | Nach Darstellung von SMC-Research musste Bio-Gate wegen Auftragsverschiebungen die Jahresprognose für 2024 reduzieren. SMC-Analyst Holger Steffen sieht immer noch hohes Potenzial in dem Geschäft, aber... ► Artikel lesen |
Das Unternehmen INNATE PHARMA SA ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,14 % bei einem Aktienkurs von 1,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.
